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Preface	
	
Patients	 with	 chronic	 arthritis	 have	 seen	 enormous	 progress	 not	 only	 in	 the	
understanding	of	disease	mechanisms	but	also	in	the	development	and	introduction	
into	 clinical	 practice	 of	 new	 drugs	 and	 strategies.	 For	 patients	 with	 systemic	
autoimmune	diseases,	more	hope	appears	to	be	on	the	horizon	as	these	fields	aim	
to	 catch	up	with	 the	arthritis	 community.	 Innovative	 research	 remains	essential	 to	
cover	new	grounds	and	to	provide	solutions	for	lingering	clinical	problems.	This	issue	
of	Best	 Practice	 and	 Research	 Clinical	 Rheumatology	has	 a	 focus	 on	 new	 research	
areas	in	musculoskeletal	and	autoimmune	diseases.	Many	observations	summarized	
in	 the	 different	 reviews	 show	 that	 new	 approaches,	 novel	 technologies	 and	
previously	 uncharted	 territory	 are	 currently	 under	 intense	 investigation	 and	 may	
bring	important	insights	towards	the	clinic.	
Catrina	and	van	der	Woude	highlight	the	relationships	between	immunogenetics	and	
the	 development	 of	 rheumatoid	 arthritis.	 The	 growing	 knowledge	 and	 the	 intense	
interest	 into	 the	 events	 occurring	 before	 clinical	 arthritis	 develops,	 illustrates	 how	
researchers	 and	 clinicians	 in	 this	 field	 are	 gradually	 moving	 towards	 potential	
prevention	of	disease.	In	spondyloarthritis,	the	immune	landscape	has	recently	been	
redesigned.	 Venken	 and	 Elewaut	 discuss	 how	 the	 identification	 of	 novel,	 often	
relatively	 rare,	 cytokine-producing	 immune	cell	populations	are	being	documented	
in	 patients	 with	 spondyloarthritis	 and	 become	 part	 of	 a	 complex	 inflammatory	
network.	They	also	indicate	a	number	of	challenges	in	the	field.	
Inflammation	 is	 a	 necessary	 and	 therefore	 often-helpful	 process	 in	 physiology,	
provided	a	 return	 to	homeostasis	 can	be	 achieved.	 Therefore,	 our	body	 can	use	 a	
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number	of	 inflammation	 resolving	 systems	 that	 control	 this	 return	 to	homeostasis	
after	an	infection	or	another	immune	challenge.	The	team	of	Ioan-Facsinay	discusses	
how	such	mediators	of	inflammation	may	be	derived	from	lipids	and	what	their	roles	
could	be	 in	 rheumatoid	arthritis	and	osteoarthritis	 respectively.	Another	 important	
challenge	 in	osteoarthritis	has	been	 the	study	of	genetic	 factors	 that	contribute	 to	
disease	 and	 more	 in	 particular	 how	 to	 integrate	 these	 findings	 into	 a	
pathophysiological	paradigm.	A	growing	number	of	research	teams	are	investing	into	
this.	 The	 team	 of	 Meulenbelt	 illustrates	 how	 this	 can	 be	 done	 using	 practical	
examples.	
Insights	into	disease	mechanisms	and	the	development	of	therapeutics	are	often	not	
possible	 without	 involving	 animal	 research.	 Stakeholders	 and	 the	 general	 public	
increasingly	question	such	an	approach.	Therefore	there	is	a	clear	need	to	optimize	
these	 types	 of	 experiments.	 A	 chapter	 on	 preclinical	 imaging	 by	 vande	 Velde	 and	
Marenzana	 shows	 how	 modern	 imaging	 is	 a	 great	 tool	 to	 do	 better	 research,	
quantify	data	over	time	and	thereby	refine	and	reduce	the	use	of	animal	models.	
In	the	chapter	from	Young	and	coll.		the	authors	illustrate	how	metabolomics	can	be	
used	not	only	 to	stratify	patients	but	also	to	predict	 	 response	to	treatment,	a	key	
achievement	in	personalized	medicine.		
A	 better	 understanding	 of	 the	 pathogenic	 process	 and	 histological	 involvement	 is	
also	 deemed	 critical	 to	 discriminate	 different	 processed	 and	 to	 support	 a	 process	
driven	 therapeutic	 approach	 in	 conditions	 whose	 clinical	 spectrum	 is	 broad	 and	
often	overlapping.	The	review	provided	in	this	issue	by	Dr.	Colafrancesco	focuses	on	
the	importance	of	the	integrated	use	of	histology	and	serum	detection	of	myositis-
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associated	autoantibodies,	again	highlighting	the	use	of	tools	suitable	for	diagnosis	
purposes	but	also	to	stratify	patients	according	to	disease	severity	and	prognosis.		
Dr.	Del	 Papa	provides	 a	 detailed	overview	on	 the	new	 therapeutic	 approaches	 for	
scleroderma,	 a	 complex	 autoimmune	 disease	 whose	 pathogenesis	 encompasses	
vascular	 injury,	 autoimmunity	 and	 fibrosis.	Accordingly,	 the	authors	 suggest	 that	 a	
comprehensive	therapeutic	strategy	for	scleroderma	has	to	consider	the	targeting	of	
the	 immuno-mediated	 inflammatory	 activity,	 the	 microvascular	 abnormalities	 and	
the	 fibrotic	 changes.	This	 review,	while	 reflecting	on	 the	significant	progress	made	
on	 the	 identification	 of	molecular	 pathways	 involved	 in	 Scleroderma	pathogenesis	
still	 highlights	 the	 paucity	 of	 treatment	 options	 for	 skin	 and	 internal	 organ	
manifestations.		
A	 different	 therapeutic	 horizon	 is	 instead	 prospecting	 for	 Sjogren’s	 syndrome	 as	
reviewed	 by	 Nocturne	 and	 coll..	 The	 efforts	 made	 to	 define	 clearer	 measures	 of	
outcome	 for	 Sjogren’s	 syndrome	 and	 the	 increased	 understanding	 of	 the	 disease	
pathogenesis	 has	 supported	 the	 development	 of	 novel	 therapies,	 alongside	 the	
repurposing	 of	 drugs	 from	 alternative	 indications	 for	 this	 disease.	 While	 novel	
biological	compounds	are	currently	tested	in	early	phases	clinical	trials	the	data	are	
already	 available	 from	 the	 first	 studies	 using	 B	 cell	 targeting	 therapies	 are	
summarized	in	the	chapter	alongside	limitations	and	reflection	on	study	design	and	
future	prospects.		
Systemic	 lupus	erythematous	 (SLE)	 also	 represents	 a	 relatively	novel	 indication	 for	
biological	 treatment.	 Whilst,	 SLE	 suffered	 in	 early	 phases	 clinical	 trial	 because	 of	
mistakes	 in	 trial	 design	and	outcome	measures,	 some	of	B	 cell	 targeting	 therapies	
have	been	success	in	randomized	clinical	trials	as	described	in	the	review	by	Bakshi	
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et	coll..	The	authors	finally	reflect	in	the	possibility	ti	use	anti-T	cell	and	anti-cytokine	
therapies	for	this	condition.		
As	guest	editors,	we	hope	that	the	articles	provided	in	this	issue	spark	discussion	and	
trigger	 interest	 by	 researcher	 and	 clinicians	 to	 further	 contribute	 to	 better	
understanding	 and	 in	 the	 longer	 term	 treatment	 of	 the	 different	 disease	 the	
rheumatology	community	is	concerned	with.	
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